Fitzgerald/p16 antibody/10R-10338/100 ug
商品编号：
10R-10338-100ug
品牌：
fitzgerald-fii
市场价：
¥7500.00
美元价：
5625.00
产品分类：
功能性抗体
公司分类：
Functional_antibody
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
OVERVIEW:
| Synonyms | Monoclonal p16 antibody, Anti-p16 antibody, CDKN2A antibody, ARF antibody, CDK4I antibody, CDKN2 antibody, CMM2 antibody, INK4 antibody, INK4A antibody, MLM antibody, MTS-1 antibody, MTS1 antibody, P14 antibody, P14ARF antibody, P16 antibody, P16-INK4A antibody, P16INK4 antibody, P16INK4A antibody, P19 antibody, P19ARF antibody, TP16 antibody, Cyclin-dependent kinase inhibitor 2A multiple tumor suppressor 1 antibody |
|---|---|
| Specificity | p16 antibody recognizes p16 expression in HCC |
| Applications | ELISA, IHC |
| Immunogen | p16 antibody was raised in Mouse using a synthetic peptide (KLH-coupled) corresponding to the residues of p16 protein as the immunogen |
SPECIFICATIONS:
| Host | Mouse |
|---|---|
| Clone | M78708 |
| Isotype | IgG2a |
| Form & Buffer | Supplied in citrate-tris-HCl buffer, pH 7.0 with 0.02% Proclin 300 |
| Concentration | 1 mg/ml |
STORAGE & SAFETY:
| Storage | Store at -20 deg C for 1 year, store at 2-8 deg C for up to 1 month |
|---|
GENERAL INFORMATION:
| Product Use | Monoclonal CDKN2A/p16 antibody specific for Human p16 for use in ELISA and Immunohistochemistry. |
|---|---|
| Biological Significance | CDKN2A/p16 is a cell-cycle regulatory protein that interacts with CDK4 and CDK6, inhibiting their ability to interact with cyclins D. Inhibits the phosphorylation of the retinoblastoma protein by CDK4 or CDK6, and entry into the S phase of the cell cycle. The p16INK4A and p14ARF proteins are encoded by CDKN2A. CDKN2A is inactivated in 72% of cases of lung squamous cell carcinoma: 21% by epigenetic silencing by methylation, 18% inactivating mutation, 4% by exon 1b skipping, and 29% by homozygous deletion. CDKN2A/p16 is capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2-induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. |
| Expression | CDKN2A/p16 is located on chromosome 9 (9p21.3). This gene generates several transcript variants that differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4. The remaining transcript includes an alternate exon 1 located 20 kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein that is structurally unrelated to the products of the other variants. p16 is located in the nucleus and cytoplasm of endothelial cells. |
| Implications in Disease | Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome, Li-Fraumeni syndrome, and the melanoma-astrocytoma syndrome. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma. Mutations in the CDKN2A gene are associated with increased risk of a wide range of cancers and alterations of the gene are frequently seen in cancer cell lines including pancreatic adenocarcinoma.Homozygous deletion of p16 are frequently found in esophageal cancer and gastric cancer cell lines. Hypermethylation of tumor suppressor genes has been implicated in various cancers. Tissue samples of primary oral squamous cell carcinoma (OSCC) display hypermethylation in the promoter regions of p16. Cancer cells show a significant increase in the accumulation of methylation in CpG islands in the promoter region of p16. This epigenetic change leads to the loss of tumor suppressor gene function. |
| Sequence Information | p16 is found in an open reading frame of 148 amino acids encoding a protein of molecular weight 15,845 comprising four ankyrin repeats. |
| Post-Translational Modifications | Phosphorylation of CDKN2A/p16 seems to increase interaction with CDK4. CDKN2A/p16 is ubiquitinated in normal cells by TRIP12 via the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination at the N-terminus, regardless of the absence of lysine residues. Ubiquitination of CDKN2A/p16 leads to its degradation. In cancer cells, however, TRIP12 is located in a different cell compartment, preventing ubiquitination and degradation. |
| Database Links | Entrez Gene: 1029 Human, Omim: 600160 Human, SwissProt: P42771 Human, Unigene: 512599 Human |
品牌介绍
美国Fitzgerald 公司是一家国际性知名抗体研发生产企业。Fitzgerald公司为全球试剂诊断公司与研究机构提供专业的抗体、纯化抗原以及工业诊断用大包装免疫原料。公司产品多达5000种，能够满足您对于最前沿科学研究的需求。产品涉及：单克隆抗体／抗原生育类、传染病类、TORCH系列、肿瘤标记物、心脏标记物、神经科学类、病毒类等等。
品牌分类
重组蛋白
联络我们
